APA

Singh A., Lun X., Jayanthan A., Obaid H., Ruan Y., Strother D., Chi S. N., Smith A., Forsyth P. & Narendran A. (20131223). Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. : Molecular oncology.

Chicago

Singh Anjali, Lun Xueqing, Jayanthan Aarthi, Obaid Halah, Ruan Yibing, Strother Douglas, Chi Susan N, Smith Amy, Forsyth Peter and Narendran Aru. 20131223. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. : Molecular oncology.

Harvard

Singh A., Lun X., Jayanthan A., Obaid H., Ruan Y., Strother D., Chi S. N., Smith A., Forsyth P. and Narendran A. (20131223). Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. : Molecular oncology.

MLA

Singh Anjali, Lun Xueqing, Jayanthan Aarthi, Obaid Halah, Ruan Yibing, Strother Douglas, Chi Susan N, Smith Amy, Forsyth Peter and Narendran Aru. Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib. : Molecular oncology. 20131223.